Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mitsuyasu Tabo is active.

Publication


Featured researches published by Mitsuyasu Tabo.


ACS Medicinal Chemistry Letters | 2013

Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties

Ikumi Hyohdoh; Noriyuki Furuichi; Toshihiro Aoki; Yoshiko Itezono; Haruyoshi Shirai; Sawako Ozawa; Fumio Watanabe; Masayuki Matsushita; Masahiro Sakaitani; Pil-Su Ho; Kenji Takanashi; Naoki Harada; Yasushi Tomii; Kiyoshi Yoshinari; Kazutomo Ori; Mitsuyasu Tabo; Yuko Aoki; Nobuo Shimma; Hitoshi Iikura

A facile methodology effective in obtaining a set of compounds monofluorinated at various positions (fluorine scan) by chemical synthesis is reported. Direct and nonselective fluorination reactions of our lead compound 1a and key intermediate 2a worked efficiently to afford a total of six monofluorinated derivatives. All of the derivatives kept their physicochemical properties compared with the lead 1a and one of them had enhanced Raf/MEK inhibitory activity. Keeping physicochemical properties could be considered a benefit of monofluorinated derivatives compared with chlorinated derivatives, iodinated derivatives, methylated derivatives, etc. This key finding led to the identification of compound 14d, which had potent tumor growth inhibition in a xenograft model, excellent PK profiles in three animal species, and no critical toxicity.


Journal of Pharmacological and Toxicological Methods | 2010

Sensitivity of common marmosets to detect drug-induced QT interval prolongation: Moxifloxacin case study

Ryuichi Komatsu; Masaki Honda; Henry Holzgrefe; Jun-ichi Kubo; Yuichiro Yamada; Takehito Isobe; Kazuya Kimura; Toshio Itoh; Norikazu Tamaoki; Mitsuyasu Tabo

INTRODUCTION Moxifloxacin is the most widely used positive reference agent in clinical cardiac repolarization studies, but it has not been characterized in common marmosets which are uniquely suited to studies in early-stage development due to their small size and minimal test article requirements. The purpose of this study was to evaluate the sensitivity of the common marmoset to detect moxifloxacin-associated QT interval prolongation. METHODS Eight telemetered common marmosets were monitored for 24 h following oral administration of moxifloxacin by gavage at 0, 10, 30, and 100 mg/kg using a Latin square design. Concurrently, a pharmacokinetic evaluation in 8 non-telemetered animals was conducted. A rate-corrected QT (QTc) interval was derived using an individual probabilistic QT rate-correction. QTc (placebo-adjusted QTc change from the individual baseline) was calculated and the relationship between pharmacokinetics (PK) and pharmacodynamics (PD) was analyzed. RESULTS A slight, but not significant, increase in QTc was detected with 10 mg/kg of moxifloxacin. Moxifloxacin at 30 and 100 mg/kg elicited dose-dependent increases in QTc of 14.0+/-3.6 and 35.0+/-6.2 ms, respectively, with associated total moxifloxacin C(max) values of 6.5+/-0.5 and 16.5+/-1.6 microg/mL, respectively. From the PK/PD relationship, the plasma concentration which would attain QTc of 5 to 10 ms was estimated to be 1.67-3.73 microg/mL. The results were consistent with typical clinical trial results (QTc of 6.6-14.8 ms at 2.5-3.5 microg/mL). CONCLUSIONS The present study demonstrates that the common marmoset is highly sensitive to moxifloxacin-associated changes in cardiac repolarization, assessed as QTc. As such, this species is suitable for precise and reliable detection of small, but significant, drug-associated increases in QTc interval. Thus, the common marmoset should be regarded as a validated animal model for the detection of QT risk in early-stage drug development and represents an important addition to the current in vivo armamentarium.


Bioorganic & Medicinal Chemistry Letters | 2013

The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.

Toshihiro Aoki; Ikumi Hyohdoh; Noriyuki Furuichi; Sawako Ozawa; Fumio Watanabe; Masayuki Matsushita; Masahiro Sakaitani; Kazutomo Ori; Kenji Takanashi; Naoki Harada; Yasushi Tomii; Mitsuyasu Tabo; Kiyoshi Yoshinari; Yuko Aoki; Nobuo Shimma; Hitoshi Iikura

Introducing a sulfamide moiety to our coumarin derivatives afforded enhanced Raf/MEK inhibitory activity concomitantly with an acceptable PK profile. Novel sulfamide 17 showed potent HCT116 cell growth inhibition (IC50=8 nM) and good PK profile (bioavailability of 51% in mouse), resulting in high in vivo antitumor efficacy in the HCT116 xenograft (ED50=4.8 mg/kg). We confirmed the sulfamide moiety showed no negative impact on tests run on the compound to evaluate DMPK (PK profiles in three animal species, CYP inhibition and CYP induction) and the safety profile (hERG and AMES tests). Sulfamide 17 had favorable properties that warranted further preclinical assessment.


ACS Medicinal Chemistry Letters | 2014

Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning

Toshihiro Aoki; Ikumi Hyohdoh; Noriyuki Furuichi; Sawako Ozawa; Fumio Watanabe; Masayuki Matsushita; Masahiro Sakaitani; Kenji Morikami; Kenji Takanashi; Naoki Harada; Yasushi Tomii; Koji Shiraki; Kentaro Furumoto; Mitsuyasu Tabo; Kiyoshi Yoshinari; Kazutomo Ori; Yuko Aoki; Nobuo Shimma; Hitoshi Iikura

Substituting a carbon atom with a nitrogen atom (nitrogen substitution) on an aromatic ring in our leads 11a and 13g by applying nitrogen scanning afforded a set of compounds that improved not only the solubility but also the metabolic stability. The impact after nitrogen substitution on interactions between a derivative and its on- and off-target proteins (Raf/MEK, CYPs, and hERG channel) was also detected, most of them contributing to weaker interactions. After identifying the positions that kept inhibitory activity on HCT116 cell growth and Raf/MEK, compound 1 (CH5126766/RO5126766) was selected as a clinical compound. A phase I clinical trial is ongoing for solid cancers.


Journal of Pharmacological and Toxicological Methods | 2010

Application of probabilistic analysis for precisely correcting the QT interval for heart rate in telemetered common marmosets.

Masaki Honda; Ryuichi Komatsu; Henry Holzgrefe; Yuichiro Yamada; Takehito Isobe; Kazuya Kimura; Toshio Itoh; Norikazu Tamaoki; Mitsuyasu Tabo

INTRODUCTION QT intervals are strongly influenced by preceeding heart rate history and are also characterized by rate-independent variability, leading to difficulty in precise rate-correction of the raw QT interval. The present study elucidates a novel analytical method that effectively addresses this problematic phenomenon in telemetered common marmosets. METHODS ECGs were collected from telemetered common marmosets (male and female) and analyzed by computerized algorithms. Descriptive statistics were calculated from the mean of QT intervals for 5-ms increments of RR. The QT interval was corrected for the RR interval by applying Bazetts, Fridericias, and individual probabilistic QT rate-correction formulae. RESULTS The linear regression of log-transformed QT and RR intervals derived from a probabilistic approach yielded a well-correlated QT-RR fit. Assessed as the slope of the QTc-RR interval, application of individual probabilistic QT rate-corrections resulted in the most effective dissociation of the effects of rate from the raw QT interval, compared to generic rate-correction formulae. Using individual corrections, the QTc was stable while the interquartile range (IQR) of the QTc distribution was stable, spanning 5-10 ms for each subject over all physiological RR intervals. Heart rate variability distributions were centered about unity during both photoperiods and sinus arrhythmia was far less pronounced compared with measurements in dogs. DISCUSSION Probabilistic QT rate-correction eliminated the confounding effects of heart rate and provided a stable QTc baseline. These results indicate that application of this method of analysis in telemetered common marmosets results in a high degree of sensitivity for the consistent detection of small (5-10 ms) changes in the QTc interval.


Journal of Toxicological Sciences | 2016

Is an in vitro whole blood cytokine assay useful to detect the potential risk of severe infusion reaction of monoclonal antibody pharmaceuticals

Yoshika Iwata; Asako Harada; Toshiko Hara; Chiyomi Kubo; Tomoaki Inoue; Mitsuyasu Tabo; Corinne Ploix; Tobias Manigold; Heather Hinton; Masayuki Mishima

After the life-threatening cytokine release syndrome (CRS) occurred in the clinical study of the anti-CD28 monoclonal antibody (mAb) TGN1412, in vitro cytokine release assays using human blood cells have been proposed for non-clinical evaluation of the potential risk of CRS. Two basic assay formats are frequently used: human peripheral blood mononuclear cells (PBMC) with immobilized mAbs, and whole blood with aqueous mAbs. However, the suitability of the whole blood cytokine assay (WBCA) has been questioned, because an unrealistically large sample size would be required to detect the potential risk of CRS induced by TGN1412, which has low sensitivity. We performed a WBCA using peripheral blood obtained from 68 healthy volunteers to compare two high risk mAbs, the TGN1412 analogue anti-CD28 superagonistic mAb (CD28SA) and the FcγR-mediated alemutuzumab, with a low risk mAb, panitumumab. Based on the cytokine measurements in this study, the sample size required to detect a statistically significant increase in cytokines with 90% power and 5% significance was determined to be n = 9 for CD28SA and n = 5 for alemtuzumab. The most sensitive marker was IL-8. The results suggest that WBCA is a practical test design that can warn of the potential risk of FcγR-mediated alemtuzumab and T-cell activating CD28SA but, because there was apparently a lower response to CD28SA, it cannot be used as a risk-ranking tool. WBCA is suggested to be a helpful tool for identifying potential FcγR-mediated hazards, but further mechanistic understanding of the response to CD28SA is necessary before applying it to T cell-stimulating mAbs.


Journal of Toxicological Sciences | 2018

Conduction and contraction properties of human iPS cell-derived cardiomyocytes: analysis by motion field imaging compared with the guinea-pig isolated heart model

Takehito Isobe; Masaki Honda; Ryuichi Komatsu; Mitsuyasu Tabo

We used motion field imaging to characterize the conduction and contraction of a sheet of cardiomyocytes derived from human induced pluripotent stem cells (hiPS-CMs). A hiPS-CMs sheet of 2.8 mm × 2.8 mm allowed us to simultaneously measure the conduction and the contraction properties in the same cells. Pharmacological responses in the hiPS-CMs of four typical cardiac functional modulators, Na+ channel blocker (lidocaine), Ca2+ channel blocker (diltiazem), gap-junction inhibitor (carbenoxolone), and β-adrenergic stimulator (isoproterenol), were investigated, and the results were compared to those found using the isolated guinea-pig heart model perfused by the Langendorff method. The conduction speed of excitation waves in hiPS-CMs was decreased by lidocaine, diltiazem, and carbenoxolone, and increased by isoproterenol, and these results were in accordance with the changes in the conduction parameters of electrocardiogram (QRS duration, PR interval, and P duration) in the Langendorff guinea-pig heart model. The maximum speeds for contraction and relaxation, which respectively represent the contraction and relaxation kinetics of hiPS-CMs, were decreased by lidocaine and diltiazem, and increased by isoproterenol. These results also corresponded to alterations in the contractile and relaxation parameters found by measuring left ventricular pressure (LVdP/dtmax and LVdP/dtmin) in the Langendorff guinea-pig heart model. From these lines of evidence, it was suggested that hiPS-CMs enable us to evaluate the cardiac toxicities associated with conduction disturbance or contractile dysfunction, and thereby would be useful as an integrated assessment of cardiac function.


Journal of Pharmacological Sciences | 2011

Electrophysiological Characterization of Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells

Masaki Honda; Jumpei Kiyokawa; Mitsuyasu Tabo; Tomoaki Inoue


Journal of Pharmacological Sciences | 2005

QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles.

Seiji Hayashi; Yoshihide Kii; Mitsuyasu Tabo; Hitoshi Fukuda; Tetsuji Itoh; Takashi Shimosato; Hideto Amano; Mamoru Saito; Hajime Morimoto; Kiyoshi Yamada; Atsuhiro Kanda; Toshimasa Ishitsuka; Takanobu Yamazaki; Yoichi Kiuchi; Shinya Taniguchi; Tatsuya Mori; Shigekazu Shimizu; Yuji Tsurubuchi; Shun-ichi Yasuda; Shin-ichi Kitani; Chiaki Shimada; Kazuo Kobayashi; Masaharu Komeno; Chieko Kasai; Toshiyasu Hombo; Keiji Yamamoto


Journal of Pharmacological Sciences | 2005

QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles.

Yoshihide Kii; Seiji Hayashi; Mitsuyasu Tabo; Takashi Shimosato; Hitoshi Fukuda; Tetsuji Itoh; Hideto Amano; Mamoru Saito; Hajime Morimoto; Kiyoshi Yamada; Atsuhiro Kanda; Toshimasa Ishitsuka; Takanobu Yamazaki; Yoichi Kiuchi; Shinya Taniguchi; Tatsuya Mori; Shigekazu Shimizu; Yuji Tsurubuchi; Shun-ichi Yasuda; Shin-ichi Kitani; Chiaki Shimada; Kazuo Kobayashi; Masaharu Komeno; Chieko Kasai; Toshiyasu Hombo; Keiji Yamamoto

Collaboration


Dive into the Mitsuyasu Tabo's collaboration.

Top Co-Authors

Avatar

Kazuya Kimura

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Masaki Honda

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Ryuichi Komatsu

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Takehito Isobe

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Yuichiro Yamada

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Fumio Watanabe

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Hitoshi Iikura

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Ikumi Hyohdoh

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Kazutomo Ori

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Kenji Takanashi

Chugai Pharmaceutical Co.

View shared research outputs
Researchain Logo
Decentralizing Knowledge